TDP 43 News and Research

RSS

UQ research could lead to viable treatments for motor neuron disease

Research at The University of Queensland could eventually help develop viable treatments - and ultimately a cure - for motor neuron disease (MND).

26 Apr 2023

Study links astrocytic TDP-43 dysfunction to cognitive decline in dementia: Unlocking potential therapeutic strategies

...

20 Apr 2023

Designer DNA drug could be used to delay paralysis in ALS

In virtually all persons with amyotrophic lateral sclerosis (ALS) and in up to half of all cases of Alzheimer's disease (AD) and frontotemporal dementia, a protein called TDP-43 is lost from its normal location in the nucleus of the cell.

17 Mar 2023

Common RNA modification plays a key role in TDP-43-related neurodegeneration in ALS

Nearly 100% of cases of amyotrophic lateral sclerosis-;the progressive, fatal neurodegenerative disease known as ALS or Lou Gherig's disease -; involve the buildup of a protein called TDP-43.

27 Feb 2023

Expert work group examines and redefines “clinical meaningfulness” in Alzheimer’s

As the Alzheimer's disease scientific community, patients, and families seek to understand the results of clinical trials of new Alzheimer's treatments, the Alzheimer's Association convened an expert work group to discuss an important and timely issue: the "clinical meaningfulness" of results from these studies.

7 Feb 2023

USC researchers identify two promising avenues for developing new ALS treatments

Each year in the U.S., 5,000 patients receive a diagnosis of ALS, an incurable neurodegenerative disease that will likely kill them within two to five years.

7 Feb 2023

Study suggests Alzheimer’s disease diagnosis is associated with higher levels of soluble ACE2 in the human brain

Researchers investigated ACE2 (angiotensin-converting enzyme 2) levels among individuals with AD (Alzheimer’s disease).

23 Jan 2023

Study provides new insights into the pathology of LATE

Limbic predominate age-related TDP-43 encephalopathy or LATE is a recently recognized form of dementia that affects memory, thinking and social skills. It mimics Alzheimer's disease or AD (and sometimes co-exists with it), but LATE is a different condition, with its own risks and causes.

16 Dec 2022

Exploring new therapeutic targets and biomarkers for neurodegenerative disorders

In this interview, Dr. Shebna Massey discusses neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's, and more. She also discusses and explores new therapeutic targets and biomarkers for these diseases.

From Sino Biological Inc. 26 Oct 2022

TDP-43 can be useful biomarker for identifying neuropathological subtypes of frontotemporal dementia

Frontotemporal dementia (FTD) is one of the most common causes of progressive dementia in working-age people.

20 Oct 2022

Molecular probes can track the progress of protein that misbehaves in neurodegenerative diseases

A team of researchers from the IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology) has designed in silico "molecular probes" able to track the progress of a protein that misbehaves in different neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS) and Fronto-Temporal Dementia (FTD).

9 Sep 2022

Immuno-infrared sensor identifies Alzheimer's disease in the blood up to 17 years in advance

A sensor identifies misfolded protein biomarkers in the blood. This offers a chance to detect Alzheimer's disease before any symptoms occur. Researchers intend to bring it to market maturity.

21 Jul 2022

Research suggests a new pathway for developing Parkinson's disease

There is currently no cure for Parkinson's disease (PD), and one of the main difficulties for developing treatments is that we don't know exactly how or why the disease occurs.

4 Jul 2022

Research may pave the way for a future test to diagnose ALS

Amyotrophic lateral sclerosis (ALS) is a progressive disease of the nervous system. It affects nerve cells in the brain and spinal cord called motor neurons.

21 Jun 2022

New research provides credible estimates for prevalence of Alzheimer’s-like brain disorder

New National Institutes of Health-funded research shows that the prevalence of brain changes from Limbic-predominant Age-related TDP-43 Encephalopathy (LATE) may be roughly 40% in older adults and as high as 50% in people with Alzheimer's disease.

13 Jun 2022

Study provides the most definitive assessment of new non-Alzheimer’s dementia

Researchers from the University of Kentucky's Sanders-Brown Center on Aging say a paper recently published in Acta Neuropathologica is the most definitive assessment yet of the prevalence of a form of dementia classified in 2019 and now known as LATE.

13 Jun 2022

Antibiotic rifampicin attenuates C9orf72-linked dementia in genetically modified mice

What did Stephen Hawking and Mao Zedong have in common? They both suffered from Amyotrophic Lateral Sclerosis (ALS), a cure for which remains elusive. Scientists from Osaka Metropolitan University took an important step toward prevention of ALS and another brain disorder called Frontotemporal dementia (FTD) with their research on the effects of the antibiotic rifampicin on genetically modified mice.

23 May 2022

Little-known protein found to play a role in common neurodegenerative disorder

Scientists have known for years that amyloid fibrils -; fibrous, ropelike structures formed by closely linked protein molecules -; are present in the brains of patients with Alzheimer's and Parkinson's diseases and likely play a role in the progression of these disorders.

20 Apr 2022

University of Kentucky begins world’s first clinical trial for LATE

The motivation driving the work of Pete Nelson, M.D., Ph.D., is personal. His grandmother, Sylvia Becker, died with Alzheimer's disease, and he says his mother then grew terrified of developing the disease.

17 Mar 2022

Novel molecular pathway shared by two neurodegenerative disorders discovered

Scientists from two independent research teams have discovered how the mislocalization of a protein, known as TDP-43, alters the genetic instructions for UNC13A, providing a possible therapeutic target that could also have implications in treating amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other forms of dementia.

28 Feb 2022